centered image

centered image

Lawsuit Says Bristol-Myers Avoided $6.4 Bln Payment By Delaying Cancer Drug

Discussion in 'Hospital' started by The Good Doctor, Jun 5, 2021.

  1. The Good Doctor

    The Good Doctor Golden Member

    Joined:
    Aug 12, 2020
    Messages:
    9,211
    Likes Received:
    5
    Trophy Points:
    11,970
    Gender:
    Female

    A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.

    According to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.

    [​IMG]

    The lawsuit said Bristol-Myers failed to use contractually required "diligent efforts" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.

    Bristol-Myers had no immediate comment.

    The lawsuit was brought by UMB Bank NA, acting as a trustee for former Celgene shareholders it said lost out on the payments. Bristol-Myers bought Celgene in November 2019, and has valued the transaction at $80.3 billion.

    —Reuters Staff

    Source
     

    Add Reply

Share This Page

<